Further, cancer may exhibit varied TAP1 expression levels and clinical outcomes at different stages; for example, in stage 1 and 2 breast cancer, TAP1 expression is reduced, while the trend is reversed in stage 3 and 4 disease; however, TAP1 was considered a protective factor in our study [14]. The gene discussed is TAP1; the disease is breast carcinoma.